---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022580"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:55:33.291721+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC

## Summary
- Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.
- Prior $100M ELOC with Arena dated Feb 13, 2025 mutually terminated on same day.
- Company may sell shares at 96% of VWAP; maximum advance amount varies by time of notice (up to $20M).
- Issued transaction fee shares and paid $40,000 in fees (cash and shares) to Arena.
- ELOC term is 36 months; subject to ownership limitation of 9.99% and Nasdaq exchange cap until shareholder approval.

## SEC filing metadata
- accession: 0001493152-25-022580
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/0001493152-25-022580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022580
- JSON: https://secwatch.observer/filing/0001493152-25-022580.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.